

PCT

**U. S. PATENT AND TRADEMARK OFFICE
U. S. DEPARTMENT OF COMMERCE**

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

21587P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

101573363

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/US2004/040617	06 December 2004	10 December 2003
TITLE OF INVENTION		
ANTIPROTOZOAL IMIDAZOPYRIDINE COMPOUNDS		
APPLICANT(S) FOR DO/EO/US		
Tesfaye Buftu, Matthew J. Wyvratt, Michael H. Fisher		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (PCT Article 31).
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].
 - a. is attached hereto
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].

Items 11 to 20 below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A preliminary amendment.
14. An Application Data Sheet under 37 CFR 1.76.
15. A substitute specification.
16. A power of attorney and/or change of address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).
20. Other items or information:

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/573363	PCT/US2004/040617	21587P
The following fees are submitted:		
21. <input checked="" type="checkbox"/> Basic national fee.....		\$300
22. <input checked="" type="checkbox"/> Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....		\$0
All other situations.....		\$200
23. <input checked="" type="checkbox"/> Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....		\$0
Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an International Searching Authority.....		\$100
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB		\$400
All other situations.....		\$500
TOTAL OF 21, 22 and 23=		
\$400.00		
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.		
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)
50 - 100 =	0 /50	0 = 0
X \$250.00		
\$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)].		
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total Claims	55 - 20 =	35
Independent Claims	2 - 3 =	0
X \$50.00		
\$1,750.00		
Independent Claims		
X \$200.00		
\$0.00		
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		
+ \$360.00		
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =		
\$2,150.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date [37 CFR 1.492(f)].		
+		
TOTAL NATIONAL FEE =		
\$2,150.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.		
+		
TOTAL FEES ENCLOSED =		
\$2,150.00		
Amount to be refunded:		
Amount to be charged:		
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.		
b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>13-2755</u> in the amount of <u>\$2,150.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.		
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.		
SEND ALL CORRESPONDENCE TO:		
Customer No. 000210		
MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970		
		
SIGNATURE		
<u>Mitul I. Desai</u>		
NAME		
DATE: <u>March 24, 2006</u>		
PHONE #: <u>(732) 594-3190</u>		
46,661		
REGISTRATION NUMBER		

10/573363
IAP20 Rec'd PCT PTO 24 MAR 2006

**Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING
A FILING UNDER 35 U.S.C. 371**

Attorney Docket No.: 21587P

International Appln No.: PCT/US2004/040617

International Filing Date: 06 December 2004

Priority Date: 10 December 2003

Title: ANTIPROTOZOAL IMIDAZOPYRIDINE COMPOUNDS

Inventors:
Tesfaye Buftu
Matthew J. Wyvratt
Michael H. Fisher

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT 24 March 2006

EXPRESS MAIL NO. EV 660609489US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE
DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR
PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY

Kathy Klutanski DATE 3-24-06